全文获取类型
收费全文 | 7596篇 |
免费 | 664篇 |
国内免费 | 13篇 |
专业分类
耳鼻咽喉 | 58篇 |
儿科学 | 238篇 |
妇产科学 | 104篇 |
基础医学 | 887篇 |
口腔科学 | 164篇 |
临床医学 | 858篇 |
内科学 | 1480篇 |
皮肤病学 | 96篇 |
神经病学 | 426篇 |
特种医学 | 509篇 |
外科学 | 1031篇 |
综合类 | 176篇 |
一般理论 | 1篇 |
预防医学 | 854篇 |
眼科学 | 95篇 |
药学 | 600篇 |
中国医学 | 4篇 |
肿瘤学 | 692篇 |
出版年
2023年 | 44篇 |
2021年 | 79篇 |
2020年 | 72篇 |
2019年 | 106篇 |
2018年 | 141篇 |
2017年 | 108篇 |
2016年 | 131篇 |
2015年 | 119篇 |
2014年 | 189篇 |
2013年 | 271篇 |
2012年 | 365篇 |
2011年 | 339篇 |
2010年 | 218篇 |
2009年 | 178篇 |
2008年 | 330篇 |
2007年 | 359篇 |
2006年 | 327篇 |
2005年 | 292篇 |
2004年 | 298篇 |
2003年 | 272篇 |
2002年 | 273篇 |
2001年 | 268篇 |
2000年 | 284篇 |
1999年 | 215篇 |
1998年 | 107篇 |
1997年 | 98篇 |
1996年 | 89篇 |
1995年 | 112篇 |
1994年 | 100篇 |
1993年 | 80篇 |
1992年 | 185篇 |
1991年 | 168篇 |
1990年 | 157篇 |
1989年 | 149篇 |
1988年 | 183篇 |
1987年 | 153篇 |
1986年 | 123篇 |
1985年 | 145篇 |
1984年 | 103篇 |
1983年 | 101篇 |
1982年 | 60篇 |
1981年 | 56篇 |
1979年 | 94篇 |
1978年 | 68篇 |
1977年 | 49篇 |
1976年 | 52篇 |
1974年 | 55篇 |
1973年 | 62篇 |
1971年 | 42篇 |
1970年 | 43篇 |
排序方式: 共有8273条查询结果,搜索用时 15 毫秒
1.
Malinda Itchins Brandon Lau Amanda L. Hudson Helen Westman Cathy Yi Xia Sarah A. Hayes Viive M. Howell Michael Rodriguez Wendy A. Cooper Heng Wei Michael Buckland Bob T. Li Mark Li Vivek Rathi Stephen B. Fox Anthony J. Gill Stephen J. Clarke Michael J. Boyer Nick Pavlakis 《The oncologist》2020,25(8):641-649
2.
Kadakia Kunal C. Kidwell Kelley M. Barton Debra L. Schott Anne F. Hayes Daniel F. Griggs Jennifer J. Henry N. Lynn 《Breast cancer research and treatment》2019,175(1):181-189
Breast Cancer Research and Treatment - Extending adjuvant endocrine therapy (ET) beyond 5 years has been shown to improve outcomes in breast cancer; however, limited data are available... 相似文献
3.
4.
J. Kotzerke S. A. Davis R. Hayes K. J. Horadam 《The Australian journal of forensic sciences》2019,51(1):95-108
Formal registration of newborns and infants is a necessity to secure their rights for health care or education and to support law enforcement agencies in the fight against the trafficking of children or their illegal adoption. Ideally, all these requirements can be met using a newborn and infant biometric. Difficulties arise due to the small size and fragility of the infants’ physical structures and the effects of rapid physical growth. We review the literature for suitable biometrics and investigate the footprint; asking (a) if there is a time frame shortly after birth when the friction ridge skin pattern of a newborn can be reliably captured; and (b) if the footprint crease pattern is a suitable newborn and infant biometric. For (a), we were unable to confirm the existence of such a time frame. For (b), we performed automatic verification experiments on a small test set of 20 pairs of crease patterns, and then a larger test set, achieving EERs of 22.22% and 46.39%, respectively. The comparison of two dizygotic twins did not show any noteworthy performance difference. Based on these results we do not recommend the foot crease pattern as a newborn or infant biometric for automatic verification. 相似文献
5.
6.
7.
Marielle E. Yohe Christine M. Heske Elizabeth Stewart Peter C. Adamson Nabil Ahmed Cristina R. Antonescu Eleanor Chen Natalie Collins Alan Ehrlich Rene L. Galindo Berkley E. Gryder Heidi Hahn Sharon Hammond Mark E. Hatley Douglas S. Hawkins Madeline N. Hayes Andrea Hayes‐Jordan Lee J. Helman Simone Hettmer Myron S. Ignatius Charles Keller Javed Khan David G. Kirsch Corinne M. Linardic Philip J. Lupo Rossella Rota Jack F. Shern Janet Shipley Sivasish Sindiri Stephen J. Tapscott Christopher R. Vakoc Leonard H. Wexler David M. Langenau 《Pediatric blood & cancer》2019,66(10)
Overall survival rates for pediatric patients with high‐risk or relapsed rhabdomyosarcoma (RMS) have not improved significantly since the 1980s. Recent studies have identified a number of targetable vulnerabilities in RMS, but these discoveries have infrequently translated into clinical trials. We propose streamlining the process by which agents are selected for clinical evaluation in RMS. We believe that strong consideration should be given to the development of combination therapies that add biologically targeted agents to conventional cytotoxic drugs. One example of this type of combination is the addition of the WEE1 inhibitor AZD1775 to the conventional cytotoxic chemotherapeutics, vincristine and irinotecan. 相似文献
8.
Patrick Hayes H. Sherman Jonathan H. Elder J. Bradley Olson Jeffrey J. 《Journal of neuro-oncology》2022,158(2):167-177
Journal of Neuro-Oncology - In patients with previously diagnosed glioblastoma who are suspected of experiencing progression, does repeat cytoreductive surgery improve progression free survival or... 相似文献
9.
Uswa Shahzad Michael S Taccone Sachin A Kumar Hidehiro Okura Stacey Krumholtz Joji Ishida Coco Mine Kyle Gouveia Julia Edgar Christian Smith Madeline Hayes Xi Huang W Brent Derry Michael D Taylor James T Rutka 《Neuro-oncology》2021,23(5):718
For decades, cell biologists and cancer researchers have taken advantage of non-murine species to increase our understanding of the molecular processes that drive normal cell and tissue development, and when perturbed, cause cancer. The advent of whole-genome sequencing has revealed the high genetic homology of these organisms to humans. Seminal studies in non-murine organisms such as Drosophila melanogaster, Caenorhabditis elegans, and Danio rerio identified many of the signaling pathways involved in cancer. Studies in these organisms offer distinct advantages over mammalian cell or murine systems. Compared to murine models, these three species have shorter lifespans, are less resource intense, and are amenable to high-throughput drug and RNA interference screening to test a myriad of promising drugs against novel targets. In this review, we introduce species-specific breeding strategies, highlight the advantages of modeling brain tumors in each non-mammalian species, and underscore the successes attributed to scientific investigation using these models. We conclude with an optimistic proposal that discoveries in the fields of cancer research, and in particular neuro-oncology, may be expedited using these powerful screening tools and strategies. 相似文献
10.
Sarah Al-Beltagi Cristian Alexandru Preda Leah V. Goulding Joe James Juan Pu Paul Skinner Zhimin Jiang Belinda Lei Wang Jiayun Yang Ashley C. Banyard Kenneth H. Mellits Pavel Gershkovich Christopher J. Hayes Jonathan Nguyen-Van-Tam Ian H. Brown Jinhua Liu Kin-Chow Chang 《Viruses》2021,13(2)
The long-term control strategy of SARS-CoV-2 and other major respiratory viruses needs to include antivirals to treat acute infections, in addition to the judicious use of effective vaccines. Whilst COVID-19 vaccines are being rolled out for mass vaccination, the modest number of antivirals in use or development for any disease bears testament to the challenges of antiviral development. We recently showed that non-cytotoxic levels of thapsigargin (TG), an inhibitor of the sarcoplasmic/endoplasmic reticulum (ER) Ca2+ ATPase pump, induces a potent host innate immune antiviral response that blocks influenza A virus replication. Here we show that TG is also highly effective in blocking the replication of respiratory syncytial virus (RSV), common cold coronavirus OC43, SARS-CoV-2 and influenza A virus in immortalized or primary human cells. TG’s antiviral performance was significantly better than remdesivir and ribavirin in their respective inhibition of OC43 and RSV. Notably, TG was just as inhibitory to coronaviruses (OC43 and SARS-CoV-2) and influenza viruses (USSR H1N1 and pdm 2009 H1N1) in separate infections as in co-infections. Post-infection oral gavage of acid-stable TG protected mice against a lethal influenza virus challenge. Together with its ability to inhibit the different viruses before or during active infection, and with an antiviral duration of at least 48 h post-TG exposure, we propose that TG (or its derivatives) is a promising broad-spectrum inhibitor against SARS-CoV-2, OC43, RSV and influenza virus. 相似文献